8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 28, 2026·SEC
Rocket Pharmaceuticals, Inc.(RCKT)Earnings, Financials & Key Ratios
RCKT•NASDAQ
Price updated Jun 19, 2026
AboutRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.Show more
- Revenue$0
- EBITDA-$217M+17.6%
- Net Income-$223M+13.8%
- EPS (Diluted)-2.01+26.4%
- ROE-60.27%-11.3%
RCKT Key Insights
Rocket Pharmaceuticals, Inc. (RCKT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 17.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RCKT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RCKT Price & Volume
Rocket Pharmaceuticals, Inc. (RCKT) stock price & volume — 10-year historical chart
Loading chart...
RCKT Growth Metrics
Rocket Pharmaceuticals, Inc. (RCKT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.9%
Return on Capital
10 Years-39.94%
5 Years-48.13%
3 Years-54.28%
Last Year-58.05%
RCKT Recent Earnings
Rocket Pharmaceuticals, Inc. (RCKT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.42-2.4%
$0.41
Rev
—
$4M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.38+9.5%
$0.42
Rev
—
$277,778
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.45+6.3%
$0.48
Rev
—
$312,500
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.59-3.5%
$0.57
Rev
—
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.42vs $0.41-2.4% | —vs $4M |
| Q1 2026 | Feb 26, 2026 | $0.38vs $0.42+9.5% | —vs $277,778 |
| Q4 2025 | Nov 6, 2025 | $0.45vs $0.48+6.3% | —vs $312,500 |
| Q3 2025 | Aug 7, 2025 | $0.59vs $0.57-3.5% | —vs $4M |
Based on last 12 quarters of dataView full earnings history →
RCKT Peer Comparison
Rocket Pharmaceuticals, Inc. (RCKT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 |
Compare RCKT vs Peers
Rocket Pharmaceuticals, Inc. (RCKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RCKT Income Statement
Rocket Pharmaceuticals, Inc. (RCKT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 204K | 330K | 426K | 1.15M | 0 | 0 | 0 | 0 | 11.03M | 2.15M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -204K▲ 0% | -330K▼ 61.8% | -426K▼ 29.1% | -1.15M▼ 168.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -11.03M▲ 0% | -2.15M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -20.71% | -61.76% | -29.09% | -168.78% | 100% | - | - | - | - | - |
Operating Expenses | 26.74M | 70.97M | 75.9M | 134.86M | 167.25M | 224.34M | 259.66M | 273.2M | 217.49M | 213.72M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 12.54M | 17.89M | 17.53M | 27.92M | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M | 75.11M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 14.19M | 53.27M | 58.62M | 106.38M | 125.48M | 165.57M | 186.34M | 171.24M | 142.01M | 137.53M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | -186K | -250K | 0 | 0 | 0 | 0 | 0 | -11.03M | -240K |
Operating Income | -26.74M▲ 0% | -71.16M▼ 166.1% | -76.15M▼ 7.0% | -136M▼ 78.6% | -167.25M▼ 23.0% | -224.34M▼ 34.1% | -259.66M▼ 15.7% | -273.2M▼ 5.2% | -228.52M▲ 16.4% | -215.87M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 36.16% | -166.13% | -7.02% | -78.6% | -22.97% | -34.14% | -15.74% | -5.22% | 16.36% | - |
EBITDA | -26.53M | -70.83M | -75.72M | -134.86M | -161.88M | -218.08M | -252.56M | -263.83M | -217.49M | -205.69M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 36.39% | -166.94% | -6.92% | -78.09% | -20.03% | -34.72% | -15.81% | -4.46% | 17.56% | 20.93% |
D&A (Non-Cash Add-back) | 204K | 330K | 426K | 1.15M | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M | 10.18M |
EBIT | -20.21M | -68.67M | -71.56M | -132.73M | -163.18M | -219.95M | -243.72M | -256.86M | -221.23M | -206.04M |
Net Interest Income | -2.76M | -3.55M | -1.37M | -5.4M | -2.82M | 1.98M | 14.06M | 16.34M | 8.72M | 5.69M |
Interest Income | 819K | 1.69M | 3.41M | 2.15M | 3.07M | 3.89M | 15.94M | 18.22M | 10.62M | 10.42M |
Interest Expense | 3.58M | 5.24M | 4.78M | 7.55M | 5.89M | 1.91M | 1.88M | 1.89M | 1.89M | 4.73M |
Other Income/Expense | -2.76M | -3.36M | -1.12M | -3.7M | -1.82M | 2.48M | 14.06M | 14.46M | 5.39M | 6.49M |
Pretax Income | -29.5M▲ 0% | -74.52M▼ 152.6% | -77.27M▼ 3.7% | -139.7M▼ 80.8% | -169.07M▼ 21.0% | -221.86M▼ 31.2% | -245.59M▼ 10.7% | -258.75M▼ 5.4% | -223.12M▲ 13.8% | -209.38M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 6.97M | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | -4.99% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -29.5M▲ 0% | -74.52M▼ 152.6% | -83.23M▼ 11.7% | -146.67M▼ 76.2% | -169.07M▼ 15.3% | -221.86M▼ 31.2% | -245.59M▼ 10.7% | -258.75M▼ 5.4% | -223.12M▲ 13.8% | -209.38M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 31.17% | -152.63% | -11.69% | -76.22% | -15.27% | -31.23% | -10.7% | -5.35% | 13.77% | 18.85% |
Net Income (Continuing) | -29.5M | -74.52M | -77.27M | -146.67M | -169.07M | -221.86M | -245.59M | -258.75M | -223.12M | -209.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.36▲ 0% | -1.89▲ 56.7% | -1.70▲ 10.1% | -2.52▼ 48.2% | -2.68▼ 6.3% | -3.26▼ 21.6% | -2.92▲ 10.4% | -2.73▲ 6.5% | -2.01▲ 26.4% | -1.87▲ 0% |
EPS Growth % | 31.98% | 56.65% | 10.05% | -48.24% | -6.35% | -21.64% | 10.43% | 6.51% | 26.37% | 28.9% |
EPS (Basic) | -4.36 | -1.89 | -1.70 | -2.52 | -2.68 | -3.26 | -2.92 | -2.73 | -2.01 | - |
Diluted Shares Outstanding | 6.77M | 39.38M | 49.01M | 55.38M | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M | 112.13M |
Basic Shares Outstanding | 6.77M | 39.38M | 49.01M | 55.38M | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M | 112.13M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RCKT Balance Sheet
Rocket Pharmaceuticals, Inc. (RCKT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 101.05M | 209.09M | 307.75M | 487.35M | 392.06M | 364.06M | 378.22M | 378.18M | 192.73M | 149.83M |
Cash & Short-Term Investments | 100.01M | 205.73M | 304.12M | 482.72M | 388.74M | 356.39M | 373.18M | 372.34M | 188.93M | 144.38M |
Cash Only | 78.72M | 111.36M | 185.38M | 297.1M | 232.69M | 140.52M | 55.9M | 163.63M | 77.56M | 49.61M |
Short-Term Investments | 21.29M | 94.38M | 118.73M | 185.62M | 156.05M | 215.88M | 317.27M | 208.7M | 111.37M | 94.77M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 3.36M | 0 | 0 | 0 | 7.67M | 5.05M | 5.85M | 3.81M | 5.45M |
Total Non-Current Assets | 731K | 42.23M | 64.37M | 103.48M | 104.96M | 187.75M | 188.12M | 149.52M | 137.72M | 135.58M |
Property, Plant & Equipment | 563K | 2.03M | 31.35M | 70.64M | 72.35M | 77.64M | 87.59M | 83.32M | 71.59M | 69.45M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 30.82M | 30.82M | 30.82M | 30.82M | 39.15M | 39.15M | 39.15M | 39.15M | 39.15M |
Intangible Assets | 0 | 0 | 226K | 0 | 0 | 25.72M | 25.15M | 25.15M | 25.15M | 25.15M |
Long-Term Investments | 207K | 7.4M | 1.52M | 0 | 0 | 43.28M | 34.32M | 0 | 1.34M | 4.05M |
Other Non-Current Assets | -39K | 1.44M | 1.98M | 3.59M | 1.8M | 1.95M | 1.91M | 1.89M | 482K | 482K |
Total Assets | 101.78M▲ 0% | 251.31M▲ 146.9% | 372.12M▲ 48.1% | 590.82M▲ 58.8% | 497.02M▼ 15.9% | 551.81M▲ 11.0% | 566.34M▲ 2.6% | 527.7M▼ 6.8% | 330.45M▼ 37.4% | 285.41M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -21.5% | 146.92% | 48.07% | 58.77% | -15.88% | 11.02% | 2.63% | -6.82% | -37.38% | -89.01% |
Total Current Liabilities | 4.07M | 15.37M | 18.31M | 32.62M | 22.17M | 39.17M | 48.51M | 40.68M | 30.21M | 24.47M |
Accounts Payable | 451K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Payables Outstanding | 806.94 | - | - | - | - | - | - | - | - | 72.67 |
Short-Term Debt | 0 | 0 | 957K | 4.88M | 0 | 0 | 0 | 0 | 2.92M | 2.92M |
Deferred Revenue (Current) | 506K | 534K | 562K | 590K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 557K | 12.93M | 12.68M | 2M | 4.53M | 10.01M | 9.93M | 11.94M | 27.29M | 21.54M |
Current Ratio | 24.83x | 13.60x | 16.81x | 14.94x | 17.69x | 9.29x | 7.80x | 9.30x | 6.38x | 6.12x |
Quick Ratio | 24.83x | 13.60x | 16.81x | 14.94x | 17.69x | 9.29x | 7.80x | 9.30x | 6.38x | 6.12x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 49.94M | 41.9M | 46.52M | 54.69M | 20.13M | 22.95M | 25.26M | 23.78M | 23.02M | 22.9M |
Long-Term Debt | 49.54M | 41.45M | 45.05M | 35.07M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 1.44M | 19.49M | 20.05M | 20.36M | 22.33M | 22.64M | 21.96M | 88.24M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 403K | 457K | 23K | 136K | 80K | 2.6M | 2.94M | 1.14M | 1.06M | 1.06M |
Total Liabilities | 54.01M | 57.28M | 64.82M | 87.31M | 42.3M | 62.12M | 73.77M | 64.47M | 53.23M | 47.37M |
Total Debt | 49.54M | 41.45M | 47.45M | 61.7M | 22.6M | 22.87M | 25.04M | 25.5M | 24.88M | 24.76M |
Net Debt | -29.18M | -69.91M | -137.93M | -235.4M | -210.09M | -117.65M | -30.86M | -138.14M | -52.68M | -24.85M |
Debt / Equity | 1.04x | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.05x | 0.06x | 0.09x | 0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.12x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.12x |
Interest Coverage | -5.65x | -13.11x | -14.96x | -17.59x | -27.71x | -115.22x | -129.98x | -136.19x | -116.99x | -43.58x |
Total Equity | 47.76M▲ 0% | 194.04M▲ 306.2% | 307.3M▲ 58.4% | 503.52M▲ 63.9% | 454.72M▼ 9.7% | 489.69M▲ 7.7% | 492.57M▲ 0.6% | 463.23M▼ 6.0% | 277.22M▼ 40.2% | 238.04M▲ 0% |
Equity Growth % | -34.72% | 306.24% | 58.37% | 63.85% | -9.69% | 7.69% | 0.59% | -5.96% | -40.16% | -95.19% |
Book Value per Share | 7.06 | 4.93 | 6.27 | 9.09 | 7.19 | 7.19 | 5.86 | 4.89 | 2.49 | 2.12 |
Total Shareholders' Equity | 47.76M | 194.04M | 307.3M | 503.52M | 454.72M | 489.69M | 492.57M | 463.23M | 277.22M | 238.04M |
Common Stock | 68K | 452K | 548K | 610K | 645K | 791K | 903K | 1.06M | 1.08M | 1.09M |
Retained Earnings | -268.37M | -105.87M | -183.14M | -322.84M | -491.91M | -713.77M | -959.37M | -1.22B | -1.44B | -1.49B |
Treasury Stock | 263.94M | -668K | -53K | 0 | 0 | -47K | 0 | 0 | 0 | 0 |
Accumulated OCI | -16K | -127K | 20K | -42K | -161K | -357K | 319K | 66K | -31K | -112K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCKT Cash Flow Statement
Rocket Pharmaceuticals, Inc. (RCKT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -26.11M | -53.79M | -64.66M | -74.64M | -121.16M | -178.14M | -194.92M | -209.72M | -190.01M | -179.63M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 29.93% | -105.99% | -20.22% | -15.43% | -62.33% | -47.03% | -9.42% | -7.6% | 9.4% | 56.75% |
Net Income | -29.5M | -74.52M | -77.27M | -139.7M | -169.07M | -221.86M | -245.59M | -258.75M | -223.12M | -209.38M |
Depreciation & Amortization | 200K | 330K | 426K | 1.15M | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M | 10.18M |
Stock-Based Compensation | 4.04M | 13.6M | 13.37M | 18.57M | 29.24M | 31.01M | 39.41M | 43.92M | 37.06M | 35.22M |
Deferred Taxes | 654K | -484K | -1.07M | 999K | 3.15M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 522K | 2.9M | 3.6M | 29.32M | 13.53M | 370K | -9.28M | -6.19M | -6.68M | -5.66M |
Working Capital Changes | -2.03M | 4.38M | -3.73M | 15.03M | -3.39M | 6.08M | 13.46M | 1.92M | -8.3M | -9.99M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.14M | 5.89M | -2.72M | 11.02M | -4.83M | 9.67M | 0 | 0 | 0 | 0 |
Cash from Investing | 75.02M | -5.27M | -39.01M | -96.59M | 18.85M | -69.33M | -98.07M | 131.71M | 103.77M | 179.25M |
Capital Expenditures | -70K | -1.45M | -23.27M | -29.06M | -7.71M | -8.62M | -16.47M | -5.86M | -440K | -169K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 76.35M | 15.74K | 8.45M | 95K | 42.73M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -356K | -15.74K | -8.45M | -95K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 25.41K | 153.5M | 177.79M | 282.99M | 37.68M | 155.29M | 208.4M | 185.74M | 148K | 155K |
Debt Issued (Net) | 0 | 0 | 0 | 5.56M | 201K | 172K | 139K | 0 | 35K | 20K |
Equity Issued (Net) | 0 | 153.35M | 178.1M | 281.28M | 37.68M | 155.29M | 208.39M | 185.74M | 0 | 215K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -668K | 0 | -72K | 0 | -47K | 0 | 0 | 0 | 0 |
Other Financing | 19K | 148K | -313K | -3.85M | -201K | -172K | -132K | 0 | 113K | -80K |
Net Change in Cash | 48.92M▲ 0% | 94.44M▲ 93.0% | 74.12M▼ 21.5% | 111.76M▲ 50.8% | -64.63M▼ 157.8% | -92.18M▼ 42.6% | -84.58M▲ 8.2% | 107.72M▲ 227.4% | -86.1M▼ 179.9% | -221K▲ 0% |
Free Cash Flow | -26.18M▲ 0% | -55.24M▼ 111.0% | -87.93M▼ 59.2% | -103.7M▼ 17.9% | -128.88M▼ 24.3% | -186.76M▼ 44.9% | -211.39M▼ 13.2% | -215.59M▼ 2.0% | -190.45M▲ 11.7% | -179.79M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 30.65% | -110.99% | -59.18% | -17.93% | -24.28% | -44.91% | -13.19% | -1.99% | 11.66% | 15.55% |
FCF per Share | -3.87 | -1.40 | -1.79 | -1.87 | -2.04 | -2.74 | -2.52 | -2.27 | -1.71 | -1.60 |
FCF Conversion (FCF/Net Income) | 0.89x | 0.72x | 0.78x | 0.51x | 0.72x | 0.80x | 0.79x | 0.81x | 0.85x | 0.86x |
Interest Paid | 0 | 4.49M | 2.99M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 2K | 26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCKT Key Ratios
Rocket Pharmaceuticals, Inc. (RCKT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -48.78% | -61.64% | -33.2% | -36.18% | -35.29% | -46.98% | -50.01% | -54.14% | -60.27% | -70.79% |
Return on Invested Capital (ROIC) | -36.16% | -74.79% | -38.92% | -46.63% | -48.93% | -54.57% | -46.72% | -52.08% | -62.36% | -61.85% |
Debt / Equity | 1.04x | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.05x | 0.06x | 0.09x | 0.10x |
Interest Coverage | -5.65x | -13.11x | -14.96x | -17.59x | -27.71x | -115.22x | -129.98x | -136.19x | -116.99x | -43.58x |
FCF Conversion | 0.89x | 0.72x | 0.78x | 0.51x | 0.72x | 0.80x | 0.79x | 0.81x | 0.85x | 0.86x |
Related:RCKT Dividend History·RCKT Revenue History·RCKT Price History·RCKT P/E History·RCKT Financial Ratios·RCKT Institutional Holders
RCKT SEC Filings & Documents
Rocket Pharmaceuticals, Inc. (RCKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
RCKT Frequently Asked Questions
Rocket Pharmaceuticals, Inc. (RCKT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rocket Pharmaceuticals, Inc. (RCKT) grew revenue by 0.0% over the past year. Growth has been modest.
Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $209.4M for fiscal year 2025.
Dividend & Returns
Rocket Pharmaceuticals, Inc. (RCKT) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
Rocket Pharmaceuticals, Inc. (RCKT) had negative free cash flow of $179.8M in fiscal year 2025, likely due to heavy capital investments.